chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient complained of shortness of breath, dry mouth, & dry throat a few minutes after receiving her 1st dose of Moderna. Patient states symptoms only lasted a few minutes and she recovered quickly. She states her symptoms could have been related to her anxiety or asthma.
Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Medium, Systemic: Allergic: Swelling of Face / Eyes / Mouth / Tongue-Medium
Had swelling in left foot, unable to wear shoe. Had severe pain, like walking on nails. Lasted approximately 4 days and then abated. My dad thought he?d have to give up walking.
My menstrual cycle stopped. I was on the 2nd day of my cycle, which typically lasts approximately 7 days (2nd and 3rd days are the heaviest). It completely stopped the same day as my vaccination. There was slight spotting again on 8/27.
Pt received Hep A #2 & Varicella #1. With 1-2 minutes her face became red & puffy, face & head very itchy. Hives to face & head. 1 tsp of BENADRYL was given within 1 minute & Dr evaluated child. After 45 min child sym gone & she & mother went home.
Erythematous papular, vesicles and crusted lesions on trunk and spreading to neck and shoulders, bilaterally.
Patient walked from pharmacy to front of store and promptly collapsed at the front registers. He was given slight fluids by bystanders before the ambulance was called, after ambulance was called the responder on the phone informed us to stop the patients intake of fluids.
About 12-14 hours I woke up with fever, ache all over my body and a very bad headache, I took Tylenol. I  drank soup to feel better but still didn't help. I can't sleep my head hurts all the time. But it goes and goes . It's hurting all the time. I went to the doctor on Feb. 15 she gave me medication to sleep but I took it for long but still didn't help much. I can't do anything because of the headache. I don't want to take medication for rest of my life because of the headache.
1. Sore arm lasting roughly 48-60 hours post vaccination; 2. Headache lasting roughly 48 hours post vaccination; 3. Malaise lasting roughly 36-48 hours post vaccination.
Nasty rash; This case was reported by a consumer via interactive digital media and described the occurrence of rash in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was unknown.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional details were provided as follows: Age at vaccination was not reported. The age group was selected as adult as per vaccine indication. The patient nasty rash after 2nd Shingrix shot.
Arm warm at the injection site. Site elevated .25x.25 cm. Temperature 99.4 with intermittent headaches and arm is very sore.
but has not yet received third dose; This case was reported by a nurse via call center representative and described the occurrence of incomplete course of vaccination in a 29-year-old male patient who received HAB (Twinrix adult) for prophylaxis.   Co-suspect products included hepatitis A and hepatitis B vaccine pre-filled syringe device (Twinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Twinrix adult (received 1st dose on 19th November 2020) and Twinrix adult (received 2nd dose on 20th December 2020).   On an unknown date, the patient received the 3rd dose of Twinrix adult and Twinrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Twinrix adult and Twinrix Pre-Filled Syringe Device, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time of reporting, the patient did not receive 3rd dose of Twinrix adult, which led to incomplete course of vaccination. The reporter consented to follow up.
pt recv vax & devel chickenpox w/over thirty lesions;the reporting MD felt chickenpox was not r/t vax;pt devel several hundred lesions & a fever;
Beginning on Saturday after my first dose, I had a dull pain in my lower left side of my lung. The pain increased and became a surrounding pain on my entire left lung. The pain was severe. I was diagnosed with pleurisy on Monday by my doctor.
itchy rash in three places, his upper thighs and both forearms; This is a spontaneous report from a contactable consumer (patient). A male patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, lot number was not reported, expiration date was not reported), via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunization. The patient medical history and concomitant medications were not reported. It was reported that, during call consumer stated that after first injection of Pfizer COVID vaccine he got a itchy rash in three places, his upper thighs and both forearms. He stated after reading the Isreal report concerning the efficacy of the vaccine, which he states, was only 92-93% effective and after watching a Youtube video of someone who got the first shot and got a rash and then died after the second. He decided not to get the second shot. He states his rash went away after 1 - 2 months and he has been fine otherwise. Consumer states he is intrested in having an antibody test done. The outcome of the event was recovered.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
R DELTIOD NOTICE SWELLING, REDNESS, WARN TO TOUCH ON 8/11/09 EVENING. GAVE IBUPROFEN BEGAN ITCHING ON 8/12 GAVE BENADRYL ON 8/13 SYMPTOMS IMPROVED. LESS SWELLING NO MORE ITCHING.
I had a diagnosed case of the shingles in Oct. 2009.  I caught it early and never developed the rash.  My doctor suggested I get the vaccine to prevent a recurrence.  In July 2010, 8 days after I got the vaccine I felt the same symptoms in the same location, a tingling and sizzling on the left side of my face.  I went to the doctor less than two days after the symptoms started, started the medicine, and again didn't get the rash.  I'm fine now, but still feel an occasional tingling on the one side of my face.
received the adjuvant component alone; received the adjuvant component alone; This case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a 82-year-old male patient who received Herpes zoster (Shingrix) (batch number 9727R, expiry date 27th January 2023) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.  Additional details provided were as follows: Age at vaccination was not reported Pharmacist called to report that patient received the adjuvant component alone of the Shingrix vaccine which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. No further events were reported at the time of the call. Health care professional consented to follow-up by telephone.
Information has been received from a registered nurse referring to unspecified number of patients of unknown age and gender. On unknown dates, an unspecified number of doses of improperly stored PROQUAD (lot number K025766, expiration date 08-JUN-2016, dose and route were unknown) were administered to the patients. No adverse effects were reported. This is one of the two reports received from the same reporter. Additional information has been requested.
Hematoma, diagnosed cellulitis.  Treated with Levaquin for 10 days.
This spontaneous report as received from a certified medical assistant refers to a 9 month old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On an unknown date in November 2010, the patient was inadvertently administered a dose of VAQTA (dose, route of administration, lot # and expiration date were not reported). No adverse effects reported. Additional information has been requested.
Pfizer-BioNTech COVID-19 Vaccine EUA At 10pm on January 6th she started having chills and a headache. She than started with a fever and body aches. Fever 100.5 on 1/7/21 after Tylenol. Symptoms are still persisting. temp was 99.5 this morning 1 hour after taking Tylenol.
This case was reported by a healthcare professional and described the occurrence of metallic taste in a 57-year-old male subject who was vaccinated with ENGERIX B (GlaxoSmithKline). On 4 April 2008 the subject received 2nd dose of ENGERIX B (1cc, unknown, right arm). On April 2008, 30 minutes after vaccination with ENGERIX B, the subject experienced metallic taste. The subject had reported that the metallic taste was persisting. At the time of reporting the event was unresolved. The healthcare professional considered the event was possibly related to vaccination with ENGERIX B. Follow-up information was received on 13 May 2008 via a healthcare professional, who reported that that the immunization series with ENGERIX B was discontinued. The reporting healthcare professional did not consider the event to be serious. As of 02 May 2008, the event was resolved without treatment.
My symptoms began May 2, 2022 with a sore throat. It wasn't bad, so I thought it was my allergies. Then Tuesday, I found out that I had been exposed to Covid. May 4th, is when I tested positive and at that point the sore throat was waning, but I was developing some congestion. So on May 5th, I started to get a mild runny nose. May 6th, I was prescribed Paxlovid and after the first dose, my runny nose stopped and I have felt fine ever since. I was still testing positive until May 10th.
Felt ill for 24 hours after second dose; light sensitivity; similar to hangove; loss of appetite; This is a spontaneous report from a contactable consumer or other non-healthcare professional. An adult male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number was not reported), second dose via an unspecified route of administration on an unspecified date in Apr2021, as a single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. Historical vaccine given to patient previously was bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Batch/Lot number was not reported), first dose via an unspecified route of administration on an unspecified date in Apr2021, as a single for COVID-19 immunisation. The patient did not diagnose with COVID-19 prior to vaccination. The patient had not been tested for COVID-19 since the vaccination. On an unspecified date in 2021, the patient felt ill for 24 hours after second dose, light sensitivity, similar to hangover, loss of appetite. No treatment was received for the events. The outcome of the event was reported as resolved on an unspecified date.  The lot number for the vaccine BNT162B2 was not provided and will be requested during follow up.
Localized Rx to IPV. No signs of infection. Localized warm, firm swelling at site recent IPV.
arm sore; Pain; a red mark below the vaccination area on the arm; swollen; This case was reported by a pharmacist via call center representative and described the occurrence of pain in arm in a 71-year-old female patient who received Herpes zoster (Shingrix) (batch number 29RD5, expiry date 16th April 2022) for prophylaxis.   On 17th December 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than a month after receiving Shingrix, the patient experienced pain in arm, pain, erythema of extremities and swelling. On an unknown date, the outcome of the pain in arm, pain, erythema of extremities and swelling were unknown.   It was unknown if the reporter considered the pain in arm, pain, erythema of extremities and swelling to be related to Shingrix.  Additional case details were reported as follows: The patient received Shingrix and experienced arm sore, pain, a red mark below the vaccination area on the arm, swollen but not warm.  The reporter wants information about the administration of a second dose. The reporter consented to follow up.
Fatigue, body aches all over, very sore arm where injection received, alternating body temp hot and cold, nausea, headache. All started 9 hours post vaccine. Still going after 14 hrs of reactions.
No known adverse effects; a 14 year old patient received a dose of Proquad; This spontaneous report was received from a nurse and refers to a 14-year-old patient of unknown gender. No information regarding the patient's pertinent medical history, drug reactions of allergies and concomitant therapies was provided. On 08-MAY-2019, the patient of inappropriate age was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (recombinant human albumin) (PROQUAD) injection, lot # R023499 and expiration date 13-FEB-2020 (dose and route of administration were not reported) for prophylaxis. There was no known adverse effects.
injection site soreness; Headache; This is a spontaneous report from a contactable consumer(wife reported for husband). A 69-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation; Solution for injection, Lot number: EL9263 and Expiration date not reported), via an unknown route of administration on 25Jan2021, 1ST DOSE, SINGLE for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported .It was reported that, they got their first shot on 25Jan2021. She heard the vaccine was supposed to be given 3 weeks later, but they got appointments for 4 weeks later. Her and her husband got the vaccine together. On 25Jan2021 patient only had a little injection site soreness, and a headache that went away the next day. He went online to sign up. They got a call 9 days after. The injection site soreness he experienced from 25Jan2021 to 26Jan2021. He had a headache that day, 25Jan2021, and the 26Jan2021. He recovered completely from both of those. The outcome of the events was reported as recovered on 26Jan2021.  Follow-up (12May2021): Follow-up attempts completed. No further information expected.
Chief Complaint: patient with COVID s/s that started yesterday, staff at Healthcare did rapid +COVID today. received tylenol supp @ 0645, were unable to manage O2 sat at facility. 83% on RA, up to 92% now on 2L. History of Present Illness : Patient is a 70 year old of Doctor K. who recently moved Care Ct due to increased support needs physically with advancing DJD and arthritis of the hips, shoulders, and knees.  She is chronically been on alternating doses of daily prednisone for this.  She was given Pfizer COVID vaccination in February and had booster dose 2 weeks ago due to her chronically immunocompromised state.  Her sister is at the bedside today and states that there was a recent employee at care center that tested positive for Covid.  All residents were tested 2 days ago, Patient was negative but then yesterday began having a nonproductive cough with shortness of breath.  Today she began having fevers with hypoxemia and was transferred to emergency room for further evaluation.  She has tested positive for Covid today.
Patient received vaccine in early morning. By supper time he reports he was feeling ill and was dizzy and lightheaded. Was taken to ER by ambulance and was found to have fever of 103. was treated for sepsis. Initial Blood culture showed staph coagulase negative which was later determined to be a contaminant. Patient was admitted for febrile illness and sepsis although WBC was never elevated. spent 6 days in the hospital.
Patient was administered with an expired 0.5ml dose of Typhim VI with no AE; Initial information regarding an unsolicited valid non-serious case was received from a other health care professional via Medical Information (Reference number- 00631153) and transmitted to Sanofi on 07-Jun-2021.  This case involves a 51 years old female patient who received a 0.5 mL expired dose of suspect TYPHOID VI POLYSACCHARIDE VACCINE [TYPHIM VI] (batch number: R1B741M and expiry date : 23-Mar-2021) via unknown route in left deltoid (expired product administered) for prophylactic vaccination on 11-May-2021.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.  It was an actual medication error case due to expired vaccine used (latency: same day).  The patient received no other medications or vaccinations on that visit.   At the time of reporting, no adverse event was reported.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
This case was reported by a nurse and described a 12-year-old female subject who did not respond to immunization to the Engerix-B vaccination series. On 24 February 1994, the subject received 1st dose of Engerix-B. This is longer than the recommended interval of one month between the 1st and 2nd doses of Engerix-B. On 26 July 1994, the subject received the 3rd dose of Engerix-B. This is shorter than the recommended interval of six months between the 1st and 3rd doses of Engerix-B. On 10 March 2006, 11 years after the 3rd dose of Engerix-B, a hepatitis B surface antibody titer was negative.
First dose over 1 year ago; This case was reported by a other health professional via call center representative and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (Received first dose of Shingrix a year ago).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were reported as follows: Age at vaccination was not applicable for this report. The patient received a dose of Shingrix a year before reporting and have not received any dose since then. Till the time of reporting, the patient did not receive 2nd dose of vaccine, which led to incomplete course of vaccination. Consent to follow up was granted.
Felt tiredness; Sore arm; Inappropriate schedule of vaccine administered; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) and FATIGUE (Felt tiredness) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination.     Concomitant products included PARACETAMOL (TYLENOL) for an unknown indication.    On 15-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Mar-2021, the patient experienced PAIN IN EXTREMITY (Sore arm) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered). On 22-Mar-2021, the patient experienced FATIGUE (Felt tiredness). On 15-Mar-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) had resolved. On 16-Mar-2021, PAIN IN EXTREMITY (Sore arm) had resolved. At the time of the report, FATIGUE (Felt tiredness) outcome was unknown.            First dose received on 25 Feb 2021 and second dose received on 15 Mar 2021, subsequently resulted in the event inappropriate schedule of product administration.  Treatment information was not provided.   This case was linked to MOD-2021-060897 (Patient Link).
Patient reported feeling shakiness and lightheaded after initial vaccine, following 20 minute observation period patient reported feeling more normal, and left. Patient reported this is the first vaccine she has had since childhood.
2hr. post injection of Dtap #4 HIB #3, child experienced high temp of 103 degree F, Which was treated by parents with Tylenol, Since then, the has become @ normal range, but child acts "lethargic irritable and sleeping a lot" Also father states that child bowel movements have not been "normal".
pt recv vax & devel swelling @ the inj site which was treated w/ice packs for 1wk;a few wk later pt devel hives;also reports inj site becomes swollen on & off (twice a month);It remains swollen, on & off as of 4APR95;
Left arm pit sever swelling in the lymph node area; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 01Apr2021 at 08:15(at the age of 54-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient did not have any allergies to food, medications or other products. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 16:30 the patient experienced  severe swelling in the lymph node area in the left arm pit. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of adverse event and included treatment with icepacks and TYLENOL. The clinical outcome of the event severe swelling in the lymph node area in the left arm pit was recovering at the time of this report.    No follow-up attempts are needed. No further information is expected.
This case was reported by a healthcare professional and described the occurrence of passed out in a 16-year-old male subject who was vaccinated BOOSTRIX (GlaxoSmithKline). Concurrent vaccination included MENACTRA (non-gsk) (Sanofi) given on 14 July 2009. On 14 July 2009 at 11:30 the subject received unspecified dose of BOOSTRIX (unknown route, right arm). On 14 July 2009, 1 minute after vaccination with BOOSTRIX, the subject experienced passed out, eyes rolling and vomiting. This case was assessed as medically serious by GSK. On 14 July 2009, the events were resolved. The healthcare professional considered the events were possibly related to vaccination with BOOSTRIX. The healthcare professional also reported a female subject who passed out after receiving BOOSTRIX (see case ID A0798941A) and mentioned approximately 7 to 8 other cases where the subject had passed out or vomited after receiving BOOSTRIX (see case ID A0798942A).
Spoke with father on 12/7/2021.  Father reported Patient had not had any adverse effects.